menu
    • menu

    Company profile for Amerimmune

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amerimmune was started by Dr. Oral Alpan in Fairfax, Virginia, bringing a team with collective expertise of 40+ years from the National Institutes of Health. The mission of Amerimmune is to bring relevant and clinically driven immune based testing and research to practices and organizations.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AmerimmuneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1212 Waples Mill Rd #100 Fairfax, VA 22030
    Telephone
    Telephone
    571.418.4824
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amerimmune.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amerimmune/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Histogen seeks to tear up COVID-19 R&D pact and go solo
    Histogen seeks to tear up COVID-19 R&D pact and go solo

    12 Mar 2022

    // N.P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/histogen-seeks-tear-covid-19-rd-pact-and-go-solo-accuses-amerimmune-failing-push-phase-2

    N.P. Taylor FIERCEBIOTECH
    12 Mar 2022
    Share Share
    Histogen-Amerimmune’s drug shows effectiveness against Covid-19
    Histogen-Amerimmune’s drug shows effectiveness against Covid-19

    16 Aug 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/histogen-amerimmune-covid-drug/

    CLINICALTRIALSARENA
    16 Aug 2021
    Share Share
    Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study
    Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study

    16 Aug 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/08/16/2281050/0/en/Histogen-and-Amerimmune-Announce-Additional-Findings-from-its-Phase-1-Study-of-Emricasan-in-Mild-Symptomatic-COVID-19-Patients.html

    GLOBENEWSWIRE
    16 Aug 2021
    Share Share
    Histogen and Amerimmune Report Publication on Emricasan in COVID-19
    Histogen and Amerimmune Report Publication on Emricasan in COVID-19

    18 May 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/05/19/2232422/0/en/Histogen-and-Amerimmune-Report-Publication-on-Emricasan-in-COVID-19.html

    GLOBENEWSWIRE
    18 May 2021
    Share Share
    Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study
    Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study

    16 Mar 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/03/16/2193562/0/en/Histogen-and-Amerimmune-Announce-First-Patient-Dosed-in-Phase-1-Study-of-Emricasan-in-Symptomatic-COVID-19-Patients.html#:~:text=(NASDAQ%3A%20HSTO)%20and%20Amerimmune,site%20for%20the%20study%20conduct.

    GLOBENEWSWIRE
    16 Mar 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search